- Direction
- Unknown
- Own history
- —
- Peers
- 54th
- Persistence
- TRANSIENT
· Pharmaceutical Preparations
RESEARCH SNAPSHOTBausch Health Companies Inc.'s latest supported as-filed period reports revenue of $2.9B, 12.7% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 727.24% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.70% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 23.49% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 12.73% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 56.17% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value 25.95% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +5.7% from the comparable as-filed period.
Debt changed -4.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Inventory changed -3.2% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
BHC · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0000885590-26-000109SEC ↗10-QJul 30, 2026Period Jun 30, 20260000885590-26-000107SEC ↗8-KJul 29, 2026Period Jul 29, 20260000885590-26-000105SEC ↗4Jul 20, 2026Period Jul 17, 20260000885590-26-000101SEC ↗4Jul 17, 2026Period Jul 15, 20260000885590-26-000099SEC ↗4Jul 15, 2026Period Jul 14, 20260000885590-26-000097SEC ↗4Jul 2, 2026Period Jun 30, 20260000885590-26-000095SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 19, 2026Filed Aug 20, 2026 | Lenar Aimee J.President, US Pharma | Open Market SaleDirect | 36,827 | $7 | $258,894 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.sbc_revenue_ratio
Raw value 1.89% · OPTIONAL
Net income changed +74.3% from the comparable as-filed period.
Operating income changed +66.7% from the comparable as-filed period.
Operating margin changed +840 basis points from the comparable as-filed period.
Revenue changed +12.7% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0000885590-26-000093